Similarly, the combination of FLT3 inhibitors with VEN demonstrated strong antileukemic synergy in FLT3-ITD AML cell lines and patient samples, with the downregulation of MCL1 and the inhibition of p-ERK being key mechanisms [73]. This evidence concerns the gene MCL1 and acute myeloid leukemia.